Mansıroğlu, Aslı KurtarSeymen, HandeSincer, İsa2023-11-202023-11-202022Mansiroglu, A. K., Seymen, H., Sincer, I., & Gunes, Y. (2022). Evaluation of endothelial dysfunction in COVID-19 with flow-mediated dilatation. Arquivos Brasileiros de Cardiologia, 119, 319-325.0066-782Xhttp://dx.doi.org/10.36660/abc.20210561https://hdl.handle.net/20.500.12491/11859Background: Inflammation is known to play a crucial role in many diseases, including COVID-19. Objective: Using flow-mediated dilatation (FMD), we aimed to assess the effects of inflammation on endothelial function in COVID-19 patients. Methods: This study was conducted with a total of 161 subjects, of whom 80 were diagnosed with COVID-19 within the last six months (comprising 48 women and 32 men with a mean age of 32.10 +/- 5.87 years) and 81 were healthy controls (comprising 45 women and 36 men with a mean age of 30.51 +/- 7.33 years). We analyzed the findings of transthoracic echocardiography and FMD in all subjects. All results were considered statistically significant at the level of p < 0.05. Results: The echocardiography and FMD of the COVID-19 group were performed 35 days (range: 25-178) after diagnosis. There was no statistically significant difference in echocardiographic parameters. Differently, FMD (%) was significantly higher in the control group (9.52 +/- 5.98 vs. 12.01 +/- 6.18, p=0.01). In multivariate analysis with the forward stepwise model, FMD was significantly different in the control group compared to the COVID-19 group (1.086 (1.026 - 1.149), p=0.04). A Spearman's correlation test indicated that FMD (r=0.27, p=0.006) had a weak positive correlation with the presence of COVID-19. Conclusion: Our findings point to COVID-19-induced endothelial dysfunction, as assessed by FMD, in the early recovery phase.eninfo:eu-repo/semantics/openAccessCOVID-19/ComplicationsEndothelialCells/infectionRisk-FactorsCoronavirusInflammationArticle10.36660/abc.202105611192319324356745702-s2.0-85135523579Q3WOS:000841701300019Q3